Compositions and methods for the treatment of metabolic syndrome

Abstract

The invention relates to compounds of Formula I: and its pharmaceutical acceptable salts, solvates, enantiomers, stereoisomers and hydrates thereof. Compounds of Formula I and and compositions comprising Formula I are used to treat patients with metabolic syndrome and may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral administration, as a syrup, or for injection. More specifically, compounds and compositions of Formula I may be used to treatment of acute hypertension or-malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.

Dependencies are inferred from the claim text.